These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

637 related items for PubMed ID: 30272121

  • 1. Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.
    Afaq A, Bomanji J.
    Br Med Bull; 2018 Dec 01; 128(1):37-48. PubMed ID: 30272121
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Dec 01; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
    Eissa A, Elsherbiny A, Coelho RF, Rassweiler J, Davis JW, Porpiglia F, Patel VR, Prandini N, Micali S, Sighinolfi MC, Puliatti S, Rocco B, Bianchi G.
    Minerva Urol Nefrol; 2018 Oct 01; 70(5):462-478. PubMed ID: 29664244
    [Abstract] [Full Text] [Related]

  • 4. 68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer.
    Pfister D, Haidl F, Nestler T, Verburg F, Schmidt M, Wittersheim M, Steib F, Heidenreich A.
    BJU Int; 2020 Dec 01; 126(6):679-683. PubMed ID: 32531840
    [Abstract] [Full Text] [Related]

  • 5. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep 01; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Significance of PSMA imaging in prostate cancer].
    Gasch C, Düwel C, Kopka K, Kratochwil C, Vinsensia M, Eiber M, Maurer T, Haberkorn U, Hadaschik B, Giesel FL.
    Urologe A; 2017 Jan 01; 56(1):3-12. PubMed ID: 28005153
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review.
    Mattana F, Muraglia L, Rajwa P, Zattoni F, Marra G, Chiu PKF, Heidegger I, Kasivisvanathan V, Kesch CV, Olivier J, Preisser F, Thibault C, Valerio M, van den Bergh RCN, Gandaglia G, Ceci F, European Association of Urology Young Academic Urologists Prostate Cancer Working Party.
    Eur Urol Oncol; 2023 Apr 01; 6(2):128-136. PubMed ID: 36804735
    [Abstract] [Full Text] [Related]

  • 13. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
    Barbaud M, Frindel M, Ferrer L, Le Thiec M, Rusu D, Rauscher A, Maucherat B, Baumgartner P, Fleury V, Colombié M, Thierry-Morel A, Kraeber-Bodéré F, Campion L, Rousseau C.
    Prostate; 2019 Apr 01; 79(5):454-461. PubMed ID: 30549066
    [Abstract] [Full Text] [Related]

  • 14. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.
    Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.
    J Nucl Med; 2018 Feb 01; 59(2):230-237. PubMed ID: 29123013
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Performance of 68Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence.
    Bailey J, Piert M.
    Curr Urol Rep; 2017 Sep 09; 18(11):84. PubMed ID: 28889366
    [Abstract] [Full Text] [Related]

  • 18. Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy.
    Kranzbühler B, Nagel H, Becker AS, Müller J, Huellner M, Stolzmann P, Muehlematter U, Guckenberger M, Kaufmann PA, Eberli D, Burger IA.
    Eur J Nucl Med Mol Imaging; 2018 Jan 09; 45(1):20-30. PubMed ID: 29032394
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
    Lin CY, Lee MT, Lin CL, Kao CH.
    Clin Nucl Med; 2019 May 09; 44(5):365-376. PubMed ID: 30888999
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.